SeekingAlpha · Aug 5, 2026
Astellas Pharma Inc. 2027 Q1 - Results - Earnings Call Presentation
2026-08-05. The following slide deck was published by Astellas Pharma Inc.
AL
OTC · ALPMY
Astellas Pharma Inc.
Healthcare · Drug Manufacturers - General
$14.72
Up+$0.19 (+1.31%)
Updated Aug 16, 2026, 9:53 PM
SID Score
6.5/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 29.58B
- P/E ratio
- 14.43
- Dividend yield
- 3.28%
- 52-week range
- — – —
- Volume
- 4.04K
- Avg. volume
- 127.41K
Price performance
ALPMY price history
1M range · 0 trading sessions · Daily adjusted prices
ALPMY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest ALPMY news
The latest Smart Investors Daily articles mentioning ALPMY.
Stock researchCompany · Overview
ALPMY research
Overview
Company profile and research snapshot.
Company profile
ASTELLAS PHARMA UNSP/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Jul 10, 2026
Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer
FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.
Benzinga · Jun 23, 2026
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle
Sangamo files for Chapter 11 as Eli Lilly and Astellas step in to buy its valuable gene therapy and genome-editing assets.
Yahoo · Jun 11, 2026
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
